Quarterly Updates5 May 2026, 03:26 pm
Ajanta Pharma FY26 Revenue Up 17% to ₹5,453 Cr
AI Summary
Ajanta Pharma Ltd reported strong FY26 results with revenue from operations up 17% to ₹5,453 cr and profit after tax up 15% to ₹1,056 cr. Q4 FY26 revenue rose 21% to ₹1,422 cr, while PAT increased 18% to ₹267 cr. The company's India branded generics business exceeded IPM growth by 33%, driven by new launches and volume growth. Ajanta Pharma will host an earnings conference call on May 5, 2026.
Key Highlights
- FY26 revenue from operations increased by 17% to ₹5,453 cr.
- FY26 profit after tax (PAT) rose by 15% to ₹1,056 cr.
- Q4 FY26 revenue from operations grew by 21% to ₹1,422 cr.
- Q4 FY26 profit after tax (PAT) increased by 18% to ₹267 cr.
- India branded generics business exceeded IPM growth by 33%.
AJANTPHARMPharmaceuticals
AJANTA PHARMA LTD.Price Impact